The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 101–200 of 1,000
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919072 · Cited by 147
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
Moutafi, M. K., Robbins, C. T., Yaghoobi, V., Fernandez, A. I., Martínez-Morilla, S., Xirou, V., Bai, Y., Song, Y., Gaule, P., Krueger, J. S., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00804-9 · Cited by 148
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Patel, A., Unni, N. G., & Peng, Y. S. (2020) · Cancers · doi:10.3390/cancers12082081 · Cited by 147
Antibody-drug conjugates in lung cancer: dawn of a new era?
Coleman, N., Yap, T. A., Heymach, J. V., Meric‐Bernstam, F., & Le, X. (2023) · npj Precision Oncology · doi:10.1038/s41698-022-00338-9 · Cited by 145
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Indini, A., Rijavec, E., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094774 · Cited by 147
Overview of recent advances in metastatic triple negative breast cancer
O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 138
The History of Early Breast Cancer Treatment
Ben-Dror, J., Shalamov, M. M., & Sonnenblick, A. (2022) · Genes · doi:10.3390/genes13060960 · Cited by 148
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Marei, H. E. S., Cenciarelli, C., & Hasan, A. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02679-8 · Cited by 145
Zhang, G., Ren, C., Li, C., Wang, Y., Chen, B., Wen, L., Jia, M., Li, K., Mok, H., Cao, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02346-9 · Cited by 137
Resistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 139
Targeting HER2 heterogeneity in breast cancer
Hamilton, E. P., Shastry, M., Shiller, S. M., & Ren, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102286 · Cited by 142
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 135
Hammood, M., Craig, A. W., & Leyton, J. V. (2021) · Pharmaceuticals · doi:10.3390/ph14070674 · Cited by 140
Abuhelwa, Z., Alloghbi, A., Alqahtani, A. J., & Nagasaka, M. (2022) · Drugs · doi:10.1007/s40265-022-01736-w · Cited by 135
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 141
Self-citationLu, G., Nishio, N., van den Berg, N. S., Martin, B. A., Fakurnejad, S., van Keulen, S., Colevas, A. D., Thurber, G. M., & Rosenthal, E. L. (2020) · Nature Communications · doi:10.1038/s41467-020-19498-y · Cited by 132
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Rugo, H. S., Bianchini, G., Cortés, J., Henning, J., & Untch, M. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100553 · Cited by 133
Nishikawa, T., Hasegawa, K., Matsumoto, K., Mori, M., Hirashima, Y., Takehara, K., Ariyoshi, K., Kato, T., Yagishita, S., Hamada, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02558 · Cited by 131
HER2-positive advanced breast cancer treatment in 2020
Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 130
Saura, C., Modi, S., Krop, I. E., Park, Y. H., Kim, S.-B., Tamura, K., Iwata, H., Tsurutani, J., Sohn, J., Mathias, E., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.001 · Cited by 130
Self-citationSacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Goldenberg, D. M., & Sharkey, R. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1757067 · Cited by 130
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., & Alonso‐Moreno, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090802 · Cited by 125
García‐Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B., Garrido-Castro, A. C., Pascual, T., de Cubas, A. A., Xia, Y., Felsheim, B., McClure, M. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00491-x · Cited by 125
Self-citationAntibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Chang, H. L., Schwettmann, B., McArthur, H. L., & Chan, I. S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172156 · Cited by 126
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03600-2 · Cited by 122
Self-citationAntibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
Yu, J., Fang, T., Yun, C., Liu, X., & Cai, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.847835 · Cited by 128
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
Passaro, A., Janne, P. A., & Peters, S. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00013 · Cited by 126
von Arx, C., Placido, P. D., Caltavituro, A., Rienzo, R. D., Buonaiuto, R., Laurentiis, M. D., Arpino, G., Puglisi, F., Giuliano, M., & Mastro, L. D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102500 · Cited by 120
Nakamura, Y., Mizuno, N., Sunakawa, Y., Canon, J.-L. R., Galsky, M. D., Hamilton, E. P., Hayashi, H., Jérusalem, G., Kim, S. T., Lee, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00606 · Cited by 116
Self-citationCiruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 117
Rise of Antibody-Drug Conjugates: The Present and Future
Shastry, M., Gupta, A., Chandarlapaty, S., Young, M. R., Powles, T. B., & Hamilton, E. P. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390094 · Cited by 113
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso‐Sousa, R., Park, Y. H., Rimawi, M. F., Saura, C., Schneeweiß, A., Toi, M., Chae, Y. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2508668 · Cited by 126
Self-citationClinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
McAndrew, N. P., & Finn, R. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00384 · Cited by 116
Topoisomerase I inhibitors: Challenges, progress and the road ahead
Talukdar, A., Kundu, B., Sarkar, D., Goon, S., & Mondal, M. A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114304 · Cited by 115
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
García‐Álvarez, A., Papakonstantinou, A., & Oliveira, M. (2021) · Cancers · doi:10.3390/cancers13122927 · Cited by 115
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
Hartley, J. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1776255 · Cited by 109
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., & Alonso‐Moreno, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176018 · Cited by 113
Jérusalem, G., Park, Y. H., Yamashita, T., Hurvitz, S. A., Modi, S., André, F., Krop, I. E., González, X., You, B., Saura, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0837 · Cited by 111
Self-citationAltunay, B., Morgenroth, A., Beheshti, M., Vogg, A. T. J., Wong, N. C. L., Ting, H. H., Biersack, H., Stickeler, E., & Mottaghy, F. M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05094-1 · Cited by 110
Huang, X. L., Khan, M. I., Wang, J., Ali, R., Ali, S. W., Zahra, Q. U. A., Kazmi, A., Lolai, A., Huang, Y., Hussain, A., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.075 · Cited by 108
Genetic Code Expansion: Recent Developments and Emerging Applications
Huang, Y., Zhang, P., Wang, H., Chen, Y., Liu, T., & Luo, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00216 · Cited by 109
Harbeck, N., Modi, S., Pusztai, L., Ohno, S., Wu, J., Kim, S., Yoshida, A., Fabi, A., Cao, X., Joseph, R., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.019 · Cited by 106
Self-citationHackshaw, M. D., Danysh, H. E., Singh, J. C., Ritchey, M. E., Ladner, A., Taitt, C. C., Camidge, D. R., Iwata, H., & Powell, C. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05754-8 · Cited by 105
Self-citationHER2‐positive breast cancer brain metastasis: A new and exciting landscape
Zimmer, A. S., Swearingen, A. E. D. V., & Anders, C. K. (2020) · Cancer Reports · doi:10.1002/cnr2.1274 · Cited by 109
Pegram, M. D., Hamilton, E. P., Tan, A. R., Storniolo, A. M., Balic, K., Rosenbaum, A. I., Liang, M., He, P., Marshall, S. A., Scheuber, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0014 · Cited by 105
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Guo, C. W., Figueiredo, I., Gürel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.004 · Cited by 113
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Najjar, M. K., Manore, S. G., Regua, A. T., & Lo, H. (2022) · Genes · doi:10.3390/genes13112065 · Cited by 110
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
D’Arienzo, A., Verrazzo, A., Pagliuca, M., Napolitano, F., Parola, S., Viggiani, M., Caputo, R., Puglisi, F., Giuliano, M., Mastro, L. D., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102113 · Cited by 105
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 106
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Mair, M. J., Bartsch, R., Rhun, É. L., Berghoff, A. S., Brastianos, P. K., Cortés, J., Gan, H. K., Lin, N., Lassman, A. B., Wen, P. Y., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00756-z · Cited by 109
Trastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108108 · Cited by 103
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Kabraji, S. K., Ni, J., Sammons, S. L., Li, T., Swearingen, A. E. D. V., Wang, Y., Pereslete, A., Hsu, L., DiPiro, P. J., Lascola, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1138 · Cited by 103
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Ocaña, A., Amir, E., & Pandiella, A. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-1252-7 · Cited by 101
van Mackelenbergh, M., Loibl, S., Untch, M., Buyse, M. E., Geyer, C. E., Gianni, L., Schneeweiß, A., Conte, P., Piccart, M. J., Bonnefoi, H. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02241 · Cited by 103
Spring, L. M., Nakajima, E., Hutchinson, J. A., Viscosi, E., Blouin, G. C., Weekes, C. D., Rugo, H. S., Moy, B., & Bardia, A. (2021) · The Oncologist · doi:10.1002/onco.13878 · Cited by 100
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Gibbons, D. L., Fossella, F. V., Lam, V. K. L., Patel, A. B., Negrao, M. V., Le, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01113 · Cited by 101
Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 99
Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G., & Mountzios, G. (2022) · Cancers · doi:10.3390/cancers14143337 · Cited by 102
PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
Yuan, Y., Long, H., Zhou, Z., Fu, Y., & Jiang, B. (2023) · Biomolecules · doi:10.3390/biom13010093 · Cited by 101
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
Robbins, C. T., Fernandez, A. I., Han, G., Wong, S. T.-L., Harigopal, M., Podoll, M., Singh, K., Ly, A., Kuba, M. G., Wen, H. Y., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100032 · Cited by 98
Yamato, M., Hasegawa, J., Maejima, T., Hattori, C., Kumagai, K., Watanabe, A., Nishiya, Y., Shibutani, T., Aida, T., Hayakawa, I., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0554 · Cited by 100
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Can EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 96
Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C., & Curigliano, G. (2023) · Cancers · doi:10.3390/cancers15041130 · Cited by 92
Resistance to antibody–drug conjugates: A review
Li, S., Zhao, X., Fu, K., Zhu, S., Pan, C., Yang, C., Wang, F., To, K. K. W., & Fu, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.036 · Cited by 100
(2021) · doi:10.1038/s43018-021-00190-z · Cited by 92
Self-citationWilcox, J. A., Chukwueke, U. N., Ahn, M., Aizer, A. A., Bale, T., Brandsma, D., Brastianos, P. K., Chang, S., Daras, M., Forsyth, P. A., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae103 · Cited by 91
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
Desai, A. P., Abdayem, P., Adjei, A. A., & Planchard, D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.002 · Cited by 93
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
Loibl, S., Park, Y. H., Shao, Z., Huang, C., Barrios, C., Abraham, J., Prat, A., Niikura, N., Im, S., Li, W., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514661 · Cited by 89
Self-citationCancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
Pallerla, S., Abdul, A. U. R. M., Comeau, J. M., & Jois, S. D. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020779 · Cited by 90
Esapa, B., Jiang, J., Cheung, A., Chenoweth, A. M., Thurston, D. E., & Karagiannis, S. N. (2023) · Cancers · doi:10.3390/cancers15061845 · Cited by 90
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
Dı́az-Rodrı́guez, E., Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2021) · Cancers · doi:10.3390/cancers14010154 · Cited by 87
Weng, W., Meng, T., Zhao, Q., Shen, Y., Fu, G., Shi, J., Zhang, Y., Wang, Z., Wang, M., Pan, R., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1368 · Cited by 87
Breast Cancer Heterogeneity and Response to Novel Therapeutics
Baliu‐Piqué, M., Pandiella, A., & Ocaña, A. (2020) · Cancers · doi:10.3390/cancers12113271 · Cited by 88
An overview of resistance to chemotherapy in osteosarcoma and future perspectives
García-Ortega, D. Y., Cabrera-Nieto, S. A., Caro-Sánchez, C. H. S., & Cruz‐Ramos, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.18 · Cited by 90
Roles of Podoplanin in Malignant Progression of Tumor
Suzuki, H., Kaneko, M. K., & Kato, Y. (2022) · Cells · doi:10.3390/cells11030575 · Cited by 95
Wekking, D., Porcu, M., Pellegrino, B., Lai, E., Mura, G., Denaro, N., Saba, L., Musolino, A., Scartozzi, M., & Solinas, C. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102043 · Cited by 85
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P., & Thurber, G. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00869-w · Cited by 87
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84
Development of antibody‐drug conjugates in cancer: Overview and prospects
Ruan, D., Wu, H., Meng, Q., & Xu, R. (2023) · 癌症：英文版 · doi:10.1002/cac2.12517 · Cited by 83
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 84
Drug resistance in breast cancer: Mechanisms and strategies for management
Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 82
Self-citationLiao, M. Z., Lu, D., Kågedal, M., Miles, D., Samineni, D., Liu, S. N., & Li, C. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2278 · Cited by 81
Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., Sakamoto, T., Murakami, H., Kishimoto, J., Matsumoto, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.021 · Cited by 81
GPNMB: a potent inducer of immunosuppression in cancer
Lazaratos, A.-M., Annis, M. G., & Siegel, P. M. (2022) · Oncogene · doi:10.1038/s41388-022-02443-2 · Cited by 78
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
Rassy, E., Rached, L., & Pistilli, B. (2022) · The Breast · doi:10.1016/j.breast.2022.10.016 · Cited by 77
Niikura, N., Yamanaka, T., Nomura, H., Shiraishi, K., Kusama, H., YAMAMOTO, M., Matsuura, K., Inoue, K., Takahara, S., Kita, S., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00584-5 · Cited by 80
Self-citationWilding, B., Woelflingseder, L., Baum, A., Chylinski, K., Vainorius, G., Gibson, N. J., Waizenegger, I. C., Gerlach, D., Augsten, M., Spreitzer, F., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0306 · Cited by 78
Breast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 77
Rüschoff, J., Friedrich, M., Nagelmeier, I., Kirchner, M., Andresen, L., Salomon, K., Portier, B. P., Sredni, S. T., Schildhaus, H., Jasani, B., et al. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03378-5 · Cited by 76
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 80
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Hein, A., Hartkopf, A. D., Emons, J., Lux, M. P., Volz, B., Taran, F., Overkamp, F., Hadji, P., Tesch, H., Häberle, L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.033 · Cited by 75
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 81
Ohba, A., Morizane, C., Kawamoto, Y., Komatsu, Y., Ueno, M., Kobayashi, S., Ikeda, M., Sasaki, M., Furuse, J., Okano, N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02010 · Cited by 78
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Dieci, M. V., Miglietta, F., Griguolo, G., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102064 · Cited by 74
Matsuda, Y., & Mendelsohn, B. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1846714 · Cited by 74
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Nicolò, E., Bielo, L. B., Curigliano, G., & Tarantino, P. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152842 · Cited by 74
Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 75
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
